GO:0005476 carnitine:O-acyl-L-carnitine antiporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005476 describes the molecular function of exchanging cytoplasmic O-acyl-L-carnitine for mitochondrial carnitine across the inner mitochondrial membrane.
• This antiporter activity is essential for fatty acid beta-oxidation because it imports acylcarnitines into the mitochondrial matrix.
• The canonical protein carrying this activity is SLC25A20 (CACT), a member of the mitochondrial carrier family.
• Defects in this transport step cause carnitine-acylcarnitine translocase deficiency, a severe disorder of energy metabolism.
• The activity is distinct from sodium-dependent carnitine transport mediated by OCTN2 (SLC22A5) at the plasma membrane.
• Studying GO:0005476 requires integrated approaches including transport assays, metabolomics, and CRISPR-based models.
Description
GO:0005476, carnitine:O-acyl-L-carnitine antiporter activity, is a molecular function that catalyzes the exchange of carnitine and O-acyl-L-carnitine across the inner mitochondrial membrane. This transport step is a critical component of the carnitine shuttle, which moves fatty acids into the mitochondrial matrix for beta-oxidation. The reaction is defined as carnitine (mitochondrial) + O-acyl-L-carnitine (cytoplasm) = carnitine (cytoplasm) + O-acyl-L-carnitine (mitochondrial), reflecting a strict antiport mechanism. Researchers study this activity to understand energy metabolism, mitochondrial physiology, and inherited metabolic disorders. The function is carried out by specific mitochondrial carrier proteins, most notably SLC25A20, and is distinct from plasma membrane carnitine transporters such as OCTN2.
carnitine:O-acyl-L-carnitine antiporter activity At A Glance
| GO ID | GO:0005476 |
|---|---|
| GO term | carnitine:O-acyl-L-carnitine antiporter activity |
| Ontology | molecular_function |
| Synonym | carnitine/acyl carnitine carrier activity; carnitine:acyl carnitine carrier activity; fatty acyl carnitine carrier |
| Major function | Antiport of carnitine and O-acyl-L-carnitine across the inner mitochondrial membrane |
| Reaction direction | Carnitine (mitochondrial) + O-acyl-L-carnitine (cytoplasm) = carnitine (cytoplasm) + O-acyl-L-carnitine (mitochondrial) |
| Cellular location | Inner mitochondrial membrane |
| Representative gene | SLC25A20 (CACT) |
| Related activity | Sodium-dependent carnitine transport by OCTN2 (SLC22A5) at the plasma membrane |
What Is GO:0005476?
In simple terms, this GO term describes a protein machine embedded in the inner mitochondrial membrane that swaps a carnitine molecule inside the mitochondrion for an acylcarnitine molecule outside it. The QuickGO definition states: Catalysis of the reaction: carnitine (mitochondrial) + O-acyl-L-carnitine (cytoplasm) = carnitine (cytoplasm) + O-acyl-L-carnitine (mitochondrial). This antiport activity is synonymous with carnitine/acyl carnitine carrier activity, carnitine:acyl carnitine carrier activity, and fatty acyl carnitine carrier. It is a molecular_function in the Gene Ontology and is essential for shuttling fatty acids into the mitochondrial matrix for oxidation.
Why Is carnitine:O-acyl-L-carnitine antiporter activity Important in Cell Biology?
This antiporter activity is a bottleneck for mitochondrial fatty acid oxidation, and its dysfunction leads to impaired energy production, accumulation of acylcarnitines, and severe metabolic disease. Because it directly controls the flux of fatty acids into mitochondria, it is central to understanding metabolic flexibility, cardiac and skeletal muscle energetics, and inherited disorders of fatty acid oxidation. Moreover, the activity is pharmacologically relevant because some drugs and endogenous metabolites interact with carnitine transporters, influencing drug disposition and toxicity.
• Enables mitochondrial import of long-chain acylcarnitines for beta-oxidation and ATP production.
• Defects cause carnitine-acylcarnitine translocase deficiency, a life-threatening disorder with hypoketotic hypoglycemia and cardiomyopathy.
• Plays a key role in cardiac and skeletal muscle energy metabolism due to high fatty acid dependence.
• Distinguishes mitochondrial carnitine shuttling from plasma membrane carnitine uptake by OCTN2.
• Provides a target for understanding drug-induced mitochondrial toxicity and transporter-mediated drug interactions.
• Serves as a biomarker context for acylcarnitine profiles in newborn screening and metabolic diagnostics.
• Contributes to the broader family of SLC25 mitochondrial carriers with diverse transport functions.
• Relevant to metabolic reprogramming in cancer and immune cells where fatty acid oxidation is altered.
What Happens During carnitine:O-acyl-L-carnitine antiporter activity?
Substrate recognition and binding
In simple terms: The transporter recognizes and binds acylcarnitine on the cytoplasmic side and carnitine on the matrix side.
The antiporter binds O-acyl-L-carnitine from the cytoplasm and carnitine from the mitochondrial matrix with high specificity. This binding is the first step in the exchange cycle and determines substrate selectivity among different acylcarnitine species.
Conformational cycle and antiport
In simple terms: The protein changes shape to swap the two molecules across the membrane.
Following binding, the carrier undergoes conformational changes that expose the bound substrates to opposite sides of the inner mitochondrial membrane, catalyzing the strict antiport reaction. This mechanism ensures that carnitine and acylcarnitine are exchanged in a 1:1 stoichiometry without net charge imbalance.
Coupling to beta-oxidation
In simple terms: The imported acylcarnitine is then used to make energy.
Once inside the matrix, acylcarnitine is converted back to acyl-CoA by carnitine palmitoyltransferase 2 (CPT2) and enters beta-oxidation. The antiporter activity is therefore tightly coupled to the entire fatty acid oxidation pathway, and its rate can influence overall mitochondrial energy production.
Tissue-specific demands
In simple terms: Different tissues need this activity at different levels.
High-oxidative tissues such as heart and skeletal muscle rely heavily on this antiporter to sustain fatty acid oxidation. In contrast, tissues with lower fatty acid oxidation rates may express lower levels of the carrier, reflecting metabolic specialization.
Key Genes Involved in GO:0005476 carnitine:O-acyl-L-carnitine antiporter activity
The following genes and proteins are directly or functionally linked to carnitine:O-acyl-L-carnitine antiporter activity and its broader carnitine shuttle context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC25A20 | Mitochondrial carnitine-acylcarnitine carrier (CACT) that catalyzes GO:0005476 | Primary gene for studying antiporter activity and translocase deficiency |
| CPT1A | Outer mitochondrial membrane enzyme that converts acyl-CoA to acylcarnitine | Upstream of the antiporter in the carnitine shuttle |
| CPT1B | Muscle isoform of CPT1 | Tissue-specific regulation of fatty acid oxidation |
| CPT2 | Inner mitochondrial membrane enzyme that regenerates acyl-CoA | Downstream of the antiporter; defects cause CPT2 deficiency |
| SLC22A5 | Plasma membrane sodium-dependent carnitine transporter (OCTN2) | Distinct from GO:0005476 but essential for cellular carnitine uptake |
| SLC25A29 | Mitochondrial carrier with possible acylcarnitine transport roles | Candidate for alternative or redundant transport |
| SLC25A45 | Mitochondrial carrier family member | Potential substrate specificity studies |
| ACADVL | Very long-chain acyl-CoA dehydrogenase | Fatty acid oxidation enzyme linked to acylcarnitine metabolism |
| ACADM | Medium-chain acyl-CoA dehydrogenase | Relevant to acylcarnitine profiles and beta-oxidation |
| HADHA | Trifunctional protein subunit alpha | Mitochondrial fatty acid oxidation and energy metabolism |
| HADHB | Trifunctional protein subunit beta | Mitochondrial fatty acid oxidation |
| PPARA | Nuclear receptor regulating fatty acid oxidation genes | Transcriptional control of carnitine shuttle components |
| PPARGC1A | PGC-1alpha coactivator of mitochondrial biogenesis | Regulates oxidative capacity and carnitine shuttle expression |
| SLC25A1 | Mitochondrial citrate carrier | Related mitochondrial carrier for comparative studies |
| SLC25A10 | Mitochondrial dicarboxylate carrier | Related mitochondrial carrier family member |
| SLC25A12 | Mitochondrial aspartate/glutamate carrier | Related carrier for mitochondrial transport studies |
| SLC25A13 | Mitochondrial aspartate/glutamate carrier isoform | Related carrier family member |
| SLC25A15 | Mitochondrial ornithine carrier | Related carrier for comparative transport assays |
How Is carnitine:O-acyl-L-carnitine antiporter activity Regulated?
The expression and activity of the carnitine:O-acyl-L-carnitine antiporter are regulated at multiple levels. Transcriptional control is mediated by nuclear receptors such as PPARA and coactivators like PPARGC1A, which coordinate fatty acid oxidation gene programs. Substrate availability, including cellular carnitine levels maintained by SLC22A5, indirectly influences antiporter flux. Additionally, post-translational modifications and membrane lipid environment may affect carrier function, although specific mechanisms require further study.
carnitine:O-acyl-L-carnitine antiporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC25A20 | Carnitine-acylcarnitine translocase deficiency | Knockout or point-mutation cell models in hepatocytes or cardiomyocytes |
| CPT2 | CPT2 deficiency and rhabdomyolysis | Knockout myotubes for fatty acid oxidation assays |
| CPT1A | CPT1A deficiency and hypoketotic hypoglycemia | Liver-specific knockout models |
| SLC22A5 | Primary carnitine deficiency | Knockout cells for carnitine uptake studies |
| ACADVL | VLCAD deficiency | Patient-derived fibroblasts and CRISPR correction |
Carnitine-acylcarnitine translocase deficiency
Biallelic loss-of-function variants in SLC25A20 cause carnitine-acylcarnitine translocase deficiency, a severe autosomal recessive disorder characterized by hypoketotic hypoglycemia, hyperammonemia, cardiomyopathy, and early death. The disease directly results from impaired GO:0005476 activity, leading to blocked mitochondrial fatty acid oxidation and accumulation of acylcarnitines.
Secondary fatty acid oxidation disorders
Defects in other carnitine shuttle components, such as CPT1A, CPT2, and the trifunctional protein, can phenocopy aspects of translocase deficiency and highlight the importance of the antiporter within the pathway. Acylcarnitine profiles in these disorders often reflect impaired flux through the antiporter step.
Metabolic and immune implications
Altered fatty acid oxidation and carnitine metabolism have been linked to immune cell function and inflammatory diseases such as gout, where metabolic reprogramming influences innate immune responses. While direct links to GO:0005476 require further study, the pathway is relevant to broader metabolic-immune interactions.
From carnitine:O-acyl-L-carnitine antiporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC25A20 abolish mitochondrial acylcarnitine import? | SLC25A20 knockout cell line (e.g., HEK293 or HepG2) |
| Which residues are required for substrate binding? | Point-mutation knock-in of SLC25A20 in a null background |
| Can a tagged version track subcellular localization? | Knock-in of FLAG or GFP tag at the endogenous SLC25A20 locus |
| Does overexpression increase fatty acid oxidation flux? | SLC25A20 overexpression in oxidative cell types |
| How does carnitine availability affect antiporter activity? | SLC22A5 knockout or overexpression combined with transport assays |
| Can pharmacological chaperones rescue mutant carrier? | Patient-derived cells with point mutations and compound screening |
How to Study the carnitine:O-acyl-L-carnitine antiporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled transport assay | Antiporter exchange rate and substrate specificity | Functional validation of SLC25A20 variants |
| LC-MS/MS metabolomics | Acylcarnitine and carnitine levels | Diagnosis and pathway flux analysis |
| CRISPR knockout | Loss-of-function phenotype | Causal gene identification |
| Site-directed mutagenesis | Residue-level function | Structure-function studies |
| Western blot | Protein expression and stability | Variant characterization |
| Immunofluorescence | Subcellular localization | Mitochondrial targeting validation |
| Seahorse respirometry | Mitochondrial respiration | Functional impact of antiporter loss |
| Proteoliposome reconstitution | Intrinsic transport activity | Purified carrier studies |
Transport assays with radioisotopes or fluorescent substrates
Direct measurement of carnitine:O-acyl-L-carnitine antiporter activity can be performed using radiolabeled carnitine or acylcarnitine in isolated mitochondria or proteoliposomes reconstituted with the carrier. These assays quantify exchange rates and substrate specificity.
Metabolomics and acylcarnitine profiling
Mass spectrometry-based metabolomics measures acylcarnitine species in cells and tissues, providing a functional readout of antiporter activity and fatty acid oxidation flux. Abnormal profiles are characteristic of translocase deficiency.
CRISPR-based genetic models
Knockout, point-mutation, and knock-in models generated by CRISPR allow causal testing of SLC25A20 variants and their impact on mitochondrial metabolism. These models are essential for distinguishing loss-of-function from benign polymorphisms.
Imaging and protein interaction studies
Fluorescence microscopy of tagged carriers and proximity labeling can reveal localization and interaction partners within the inner mitochondrial membrane. Such approaches complement functional transport assays.
How CRISPR Can Be Used to Study GO:0005476 carnitine:O-acyl-L-carnitine antiporter activity
Knockout
CRISPR knockout of SLC25A20 creates a clean loss-of-function model to study the consequences of abolished GO:0005476 activity on fatty acid oxidation, acylcarnitine accumulation, and cellular energetics. Such models are valuable for confirming disease causality and testing rescue strategies.
Point Mutation
Introducing patient-specific missense variants into the endogenous SLC25A20 locus via CRISPR point mutation allows assessment of residual transport activity and genotype-phenotype correlations. This approach avoids artifacts from overexpression.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the SLC25A20 locus enables real-time tracking of the carrier and interaction studies without altering physiological expression levels. Tagged knock-in models are also useful for proximity proteomics.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression of SLC25A20 can test whether increased antiporter levels enhance fatty acid oxidation flux and protect against lipid stress. Overexpression models complement loss-of-function studies.
How EDITGENE Supports carnitine:O-acyl-L-carnitine antiporter activity Research
Researchers studying carnitine:O-acyl-L-carnitine antiporter activity-related genes often need to determine whether a candidate gene is causally involved in mitochondrial fatty acid oxidation, metabolic disease, or drug response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for carnitine:O-acyl-L-carnitine antiporter activity research.
Frequently Asked Questions About carnitine:O-acyl-L-carnitine antiporter activity
What is carnitine:O-acyl-L-carnitine antiporter activity?
It is a molecular function (GO:0005476) that exchanges carnitine and O-acyl-L-carnitine across the inner mitochondrial membrane, enabling fatty acid import for beta-oxidation.
What genes are involved in carnitine:O-acyl-L-carnitine antiporter activity?
The primary gene is SLC25A20 (CACT), with related genes including CPT1A, CPT1B, CPT2, and SLC22A5 in the broader carnitine shuttle.
What is the reaction catalyzed by GO:0005476?
The reaction is carnitine (mitochondrial) + O-acyl-L-carnitine (cytoplasm) = carnitine (cytoplasm) + O-acyl-L-carnitine (mitochondrial).
How is carnitine:O-acyl-L-carnitine antiporter activity different from OCTN2?
OCTN2 (SLC22A5) is a sodium-dependent plasma membrane carnitine transporter, while GO:0005476 is a mitochondrial inner membrane antiporter.
What diseases are linked to defects in this antiporter?
Carnitine-acylcarnitine translocase deficiency, caused by SLC25A20 mutations, leads to hypoketotic hypoglycemia, cardiomyopathy, and early death.
How can I study carnitine:O-acyl-L-carnitine antiporter activity in the lab?
Use transport assays, metabolomics, and CRISPR knockout or knock-in models targeting SLC25A20.
Is SLC25A20 the only gene for this activity?
SLC25A20 is the canonical carrier, but other mitochondrial carriers such as SLC25A29 may have related functions that require further study.
What are synonyms for GO:0005476?
Synonyms include carnitine/acyl carnitine carrier activity, carnitine:acyl carnitine carrier activity, and fatty acyl carnitine carrier.
Why is this antiporter important for heart function?
The heart relies heavily on fatty acid oxidation, so impaired antiporter activity can cause cardiomyopathy and energy failure.
Can CRISPR help study carnitine:O-acyl-L-carnitine antiporter activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise functional dissection of SLC25A20 and related genes.
Conclusion
GO:0005476 carnitine:O-acyl-L-carnitine antiporter activity is a fundamental mitochondrial transport function that controls fatty acid oxidation and energy homeostasis. Its central role in carnitine-acylcarnitine translocase deficiency and broader metabolic disorders makes it a key target for research and therapeutic development. Advances in CRISPR modeling and metabolomics now enable precise interrogation of this activity in health and disease.
References
- 1. Liu X. 2019. SLC Family Transporters.. Adv Exp Med Biol 1141:101-202 PMID: 31571165
- 3. Davies JS et al.. 2025. Structural basis of sodium ion-dependent carnitine transport by OCTN2.. Nat Commun 17(1):181 PMID: 41318751
- 4. de Lima JD et al.. 2023. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.. Immunol Invest 52(3):364-397 PMID: 36745138
- 8. Samodelov SL et al.. 2020. Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology.. Int J Mol Sci 21(21) PMID: 33114309
